On 12/17/24, Perspective Therapeutics Inc (NYSEAMERICAN: CATX) stock suffered a major decline of -11.8%, closing at $3.07. This decline was accompanied by normal trading volume. Relative to the market the stock has been extremely weak over the last nine months and has declined -18.6% during the last week.
Current PriceTarget Research Rating
Perspective Therapeutics has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Perspective Therapeutics has a very low Appreciation Score of 3 and a very low Power Rating of 0, and the Lowest Value Trend Rating results.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment